This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Regulatory / Regeneron Pharmaceuticals faces...
Regulatory securities fraud investigation

Regeneron Pharmaceuticals faces securities fraud investigation

Analysis based on 7 articles · First reported May 18, 2026 · Last updated May 25, 2026

Sentiment
-60
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The stock of Regeneron Pharmaceuticals fell sharply following the disclosure of the failed drug trial, leading to significant losses for shareholders. The ongoing investigation by Levi & Korsinsky could result in further financial penalties and reputational damage for Regeneron Pharmaceuticals.

Pharmaceuticals Biotechnology Legal Services
Event Summary

Regeneron Pharmaceuticals is under investigation by Levi & Korsinsky for potential securities fraud. The investigation stems from allegedly misleading statements made by Regeneron Pharmaceuticals executives, including Ryan Crowe and George Yancopoulos, regarding the prospects of their fianlimab + Libtayo drug combination. Despite optimistic projections, the Phase 3 melanoma trial for fianlimab + Libtayo failed to meet its primary endpoint against Pembrolizumab on May 16, 2026, causing Regeneron Pharmaceuticals' stock to drop significantly. Levi & Korsinsky is now seeking to represent investors who suffered losses due to these events.

Entities Involved
stock
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is facing a securities fraud investigation due to allegedly misleading statements about its fianlimab + Libtayo drug trial, which caused its stock to drop sharply after the trial failed.
Importance 100.0 Sentiment -70.0
per
Ryan Crowe
Ryan Crowe, Senior Vice President of Investor Relations at Regeneron Pharmaceuticals, made optimistic statements about the fianlimab + Libtayo trial that are now under investigation for potentially misleading investors.
Importance 60.0 Sentiment -40.0
per
George Yancopoulos
George Yancopoulos, Chief Science Officer at Regeneron Pharmaceuticals, highlighted fianlimab + Libtayo as a 'potential blockbuster' shortly before the trial failed, contributing to the allegations of misleading statements.
Importance 40.0 Sentiment -30.0
priv
Levi & Korsinsky
Importance 0.0 Sentiment 0.0
per
Joseph E. Levi
Importance 0.0 Sentiment 0.0
Relationships
Regeneron Pharmaceuticals related ↔ George Yancopoulos
Levi & Korsinsky related ↔ Joseph E. Levi
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.